Sign in →

Test Code CMVGS Cytomegalovirus Antibody, IgG, Serum


Specimen Required


Supplies: Sarstedt Aliquot Tube 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.6 mL

Collection Instructions: Centrifuge and aliquot serum into plastic vial


Useful For

Determining whether a patient has had previous exposure to or recent infection with cytomegalovirus, including pregnant women.

 

This test is not useful for screening blood or plasma donors, or neonatal screening.

Method Name

Electrochemiluminescence Immunoassay (ECLIA)

Reporting Name

CMV Ab, IgG, S

Specimen Type

Serum

Specimen Minimum Volume

0.6 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 28 days
  Frozen  180 days
  Ambient  7 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Additives (eg, biocides, antioxidants) Reject

Clinical Information

Cytomegalovirus (CMV) is a member of the Herpesviridae family of viruses and usually causes asymptomatic infection after which it remains latent in patients, primarily within bone marrow-derived cells. Primary CMV infection in immunocompetent individuals may also manifest as a mononucleosis-type syndrome, similar to primary Epstein-Barr virus infection, with fever, malaise, and lymphadenopathy.

 

Cytomegalovirus is a significant cause of morbidity and mortality among bone marrow or solid organ transplant recipients, individuals with AIDS, and other immunosuppressed patients due to virus reactivation or a newly acquired infection. Infection in these patient populations can affect almost any organ and lead to multiorgan failure. CMV is also responsible for congenital disease among newborns and is one of the TORCH infections (toxoplasmosis, other infections including syphilis, rubella, CMV, and herpes simplex virus).

 

Cytomegalovirus seroprevalence increases with age. In the US, the prevalence of CMV specific antibodies increases from approximately 36% in children aged 6 to 11 years to over 91% in adults older than 80 yearsr.(4)

Reference Values

Negative

Reference values apply to all ages.

Interpretation

Negative

Negative for CMV IgG. False negative results may occur in immunocompromised patients.

 

Borderline

Recommend follow-up testing in 10-14 days if clinically indicated.

 

Positive

CMV IgG antibodies detected, which indicate recent or remote infection.

Cautions

Sera collected very early during the acute stage of infection may have undetectable levels of cytomegalovirus (CMV) IgG.

 

The CMV IgG assay should not be used alone to diagnose CMV infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings. In cases of suspected disease, submit a second specimen for testing in 10 to 14 days.

 

The detection of CMV-specific IgG antibodies in a single sample indicates a previous exposure to CMV but is not sufficient to distinguish between an acute or latent infection.

 

The CMV IgM and IgG results should not be used alone to diagnose CMV infection. Results should be considered in conjunction with clinical presentation, patient history and other laboratory findings.

 

Performance characteristics have not been evaluated in immunosuppressed patients or organ transplant recipients and have not been established for cord blood or for testing of neonates. Immunocompromised patients may have impaired immune responses and nonreactive IgG results may be due to delayed seroconversion and, therefore, do not rule out current infection.

 

Immune complexes or other immunoglobulin aggregates present in patient specimens may cause increased nonspecific binding and produce false-positive results.

 

Potential cross-reactivity for CMV IgG with varicella-zoster virus IgG, measles IgG, mumps IgG and parvovirus B19 IgG and could not be ruled out. The potential cross-reactivity with E. coli and autoimmune markers could not be ruled out.

 

Samples should not be taken from patients receiving therapy with high biotin doses (ie, > 5 mg/day) until at least 8 hours following the last biotin administration.

Day(s) Performed

Monday through Saturday

Report Available

Same day/1 to 3 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86644

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CMVGS CMV Ab, IgG, S 22244-8

 

Result ID Test Result Name Result LOINC Value
GCMV CMV Ab, IgG, S 22244-8